Petra Suchankova1,2, Jia Yan3,4, Melanie L Schwandt5, Bethany L Stangl3, Elisabet Jerlhag2, Jörgen A Engel2, Colin A Hodgkinson6, Vijay A Ramchandani3, Lorenzo Leggio1,7. 1. Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), 10 Center Drive (10CRC/15330), Bethesda, MD 20892, USA. 2. Department of Pharmacology, The Sahlgrenska Academy at University of Gothenburg, Box 431, 405 30 Gothenburg, Sweden. 3. Section on Human Psychopharmacology, NIAAA, NIH, 10 Center Drive (10CRC/15330), Bethesda, MD 20892, USA. 4. Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, 1101 E Marshall Street, Box 980033, Richmond, VA 23298, USA. 5. Office of the Clinical Director, NIAAA, NIH, 10 Center Drive (10CRC/15330), Bethesda, MD 20892, USA. 6. Laboratory of Neurogenetics, NIAAA, NIH, 5625 Fishers Lane, Rockville, MD 20892, USA. 7. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, 121 South Main Street, Providence, RI 02912, USA.
Abstract
AIMS: The orexigenic peptide ghrelin may enhance the incentive value of food-, drug- and alcohol-related rewards. Consistent with preclinical findings, human studies indicate a role of ghrelin in alcohol use disorders (AUD). In the present study an a priori hypothesis-driven analysis was conducted to investigate whether a Leu72Met missense polymorphism (rs696217) in the prepro-ghrelin gene (GHRL), is associated with AUD, alcohol consumption and subjective responses to alcohol. METHOD: Association analysis was performed using the National Institute on Alcohol Abuse and Alcoholism (NIAAA) clinical sample, comprising AUD individuals and controls (N = 1127). Then, a post-hoc analysis using data from a human laboratory study of intravenous alcohol self-administration (IV-ASA, N = 144) was performed to investigate the association of this SNP with subjective responses following a fixed dose of alcohol (priming phase) and alcohol self-administration (ad libitum phase). RESULTS: The case-control study revealed a trend association (N = 1127, OR = 0.665, CI = 0.44-1.01, P = 0.056) between AUD diagnosis and Leu72Met. In AUD subjects, the SNP was associated with significantly lower average drinks per day (n = 567, β = -2.49, 95% CI = -4.34 to -0.64, P = 0.008) and significantly fewer heavy drinking days (n = 567, β = -12.00, 95% CI = -19.10 to -4.89, P < 0.001). The IV-ASA study further revealed that 72Met carriers had greater subjective responses to alcohol (P < 0.05) when compared to Leu72Leu both at priming and during ad lib self-administration. CONCLUSION: Although preliminary, these findings suggest that the Leu72Leu genotype may lead to increased risk of AUD possibly via mechanisms involving a lower response to alcohol resulting in excessive alcohol consumption. Further investigations are warranted. SHORT SUMMARY: We investigated whether a Leu72Met missense polymorphism in the prepro-ghrelin gene, is associated with alcohol use disorder, alcohol consumption and subjective responses to alcohol. Although preliminary, results suggest that the Leu72Leu genotype may lead to increased risk of alcohol use disorder possibly via mechanisms involving a lower response to alcohol. Medical Council on Alcohol and Oxford University Press 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
AIMS: The orexigenic peptide ghrelin may enhance the incentive value of food-, drug- and alcohol-related rewards. Consistent with preclinical findings, human studies indicate a role of ghrelin in alcohol use disorders (AUD). In the present study an a priori hypothesis-driven analysis was conducted to investigate whether a Leu72Met missense polymorphism (rs696217) in the prepro-ghrelin gene (GHRL), is associated with AUD, alcohol consumption and subjective responses to alcohol. METHOD: Association analysis was performed using the National Institute on Alcohol Abuse and Alcoholism (NIAAA) clinical sample, comprising AUD individuals and controls (N = 1127). Then, a post-hoc analysis using data from a human laboratory study of intravenous alcohol self-administration (IV-ASA, N = 144) was performed to investigate the association of this SNP with subjective responses following a fixed dose of alcohol (priming phase) and alcohol self-administration (ad libitum phase). RESULTS: The case-control study revealed a trend association (N = 1127, OR = 0.665, CI = 0.44-1.01, P = 0.056) between AUD diagnosis and Leu72Met. In AUD subjects, the SNP was associated with significantly lower average drinks per day (n = 567, β = -2.49, 95% CI = -4.34 to -0.64, P = 0.008) and significantly fewer heavy drinking days (n = 567, β = -12.00, 95% CI = -19.10 to -4.89, P < 0.001). The IV-ASA study further revealed that 72Met carriers had greater subjective responses to alcohol (P < 0.05) when compared to Leu72Leu both at priming and during ad lib self-administration. CONCLUSION: Although preliminary, these findings suggest that the Leu72Leu genotype may lead to increased risk of AUD possibly via mechanisms involving a lower response to alcohol resulting in excessive alcohol consumption. Further investigations are warranted. SHORT SUMMARY: We investigated whether a Leu72Met missense polymorphism in the prepro-ghrelin gene, is associated with alcohol use disorder, alcohol consumption and subjective responses to alcohol. Although preliminary, results suggest that the Leu72Leu genotype may lead to increased risk of alcohol use disorder possibly via mechanisms involving a lower response to alcohol. Medical Council on Alcohol and Oxford University Press 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Howard M Cann; Claudia de Toma; Lucien Cazes; Marie-Fernande Legrand; Valerie Morel; Laurence Piouffre; Julia Bodmer; Walter F Bodmer; Batsheva Bonne-Tamir; Anne Cambon-Thomsen; Zhu Chen; J Chu; Carlo Carcassi; Licinio Contu; Ruofu Du; Laurent Excoffier; G B Ferrara; Jonathan S Friedlaender; Helena Groot; David Gurwitz; Trefor Jenkins; Rene J Herrera; Xiaoyi Huang; Judith Kidd; Kenneth K Kidd; Andre Langaney; Alice A Lin; S Qasim Mehdi; Peter Parham; Alberto Piazza; Maria Pia Pistillo; Yaping Qian; Qunfang Shu; Jiujin Xu; S Zhu; James L Weber; Henry T Greely; Marcus W Feldman; Gilles Thomas; Jean Dausset; L Luca Cavalli-Sforza Journal: Science Date: 2002-04-12 Impact factor: 47.728
Authors: Giovanni Addolorato; Esmeralda Capristo; Lorenzo Leggio; Anna Ferrulli; Ludovico Abenavoli; Noemi Malandrino; Sara Farnetti; Marco Domenicali; Cristina D'Angelo; Luisa Vonghia; Antonio Mirijello; Silvia Cardone; Giovanni Gasbarrini Journal: Alcohol Clin Exp Res Date: 2006-11 Impact factor: 3.455
Authors: J R Stevenson; L M Francomacaro; A E Bohidar; K A Young; B F Pesarchick; J M Buirkle; E K McMahon; C M O'Bryan Journal: Physiol Behav Date: 2015-12-23
Authors: Marc A Schuckit; Tom L Smith; Jelger Kalmijn; Jessica Skidmore; Peyton Clausen; Alexandra Shafir; Gretchen Saunders; Hannah Bystritsky; Kim Fromme Journal: Alcohol Clin Exp Res Date: 2015-02-06 Impact factor: 3.455
Authors: Sara Landgren; Jörgen A Engel; Petri Hyytiä; Henrik Zetterberg; Kaj Blennow; Elisabet Jerlhag Journal: Behav Brain Res Date: 2011-03-15 Impact factor: 3.332
Authors: Juan L Gomez; Christopher L Cunningham; Deborah A Finn; Emily A Young; Lily K Helpenstell; Lindsey M Schuette; Tara L Fidler; Therese A Kosten; Andrey E Ryabinin Journal: Neuropharmacology Date: 2015-06-04 Impact factor: 5.250
Authors: Petra Suchankova; Staffan Nilsson; Bettina von der Pahlen; Pekka Santtila; Kenneth Sandnabba; Ada Johansson; Patrick Jern; Jörgen A Engel; Elisabet Jerlhag Journal: Addict Biol Date: 2015-06-09 Impact factor: 4.280
Authors: Melissa A Cyders; Martin H Plawecki; William Corbin; Andrea King; Denis M McCarthy; Vijay A Ramchandani; Jessica Weafer; Sean J O'Connor Journal: Alcohol Clin Exp Res Date: 2020-03-15 Impact factor: 3.455